Fundamental analysis RMD.AX (ResMed Inc.)

Updated on 07/20/2026

Method and analysis by Lubin Danilo, founder of Lubin Investment. Score computed automatically, with no human opinion.

We analyzed ResMed stock against the 10 quality criteria of Lubin Investment. The company gets a quality score of 9/10, meaning high quality, and a P/FCF valuation multiple of 28.0×.

ResMed is a quality company by our criteria, but the price does not follow: the free cash flow multiple stays high. A great company bought too expensively is still a poor investment, so this is typically one to watch while waiting for a better entry point.

Sector: Medical Instruments & Supplies. Listing: AX. Current price: 31.68 AUD.

Lubin scoring methodology

ResMed Inc. (RMD.AX)'s score is calculated automatically from 10 objective financial criteria, with no human intervention or opinion. Each criterion is validated (YES / PARTIAL / NO) based on thresholds drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran). The final score is the sum of validations.

The thresholds come from the financial literature, not from our preferences: see the valuation work of Aswath Damodaran (NYU Stern) and the SEC investor education resources (investor.gov).

The 10 quantitative criteria analyzed

1. Profitable: net margin > 5%
2. Growing revenue: revenue growing > 10%/year over 5 years
3. Growing earnings per share: FCF per share adjusted for stock-based compensation, > 10%/year over 5 years
4. Share count under control: stable or declining (net buybacks = value creation for shareholders)
5. Growing revenue per employee: revenue and revenue per employee both grow ≥ 10%/year over 5 years; partial when only one growth driver reaches its tier (fallback: free cash flow margin > 10% when employee history is unavailable)
6. Expanding margins: operating margin widens over 5 years (operating leverage)
7. Return on invested capital: Cash ROCE > 15% per year
8. Debt under control: net debt repayable in less than 3 years of free cash flow
9. Earnings converted to cash: free cash flow exceeds accounting net income
10. Net collection period: short or negative cash conversion cycle

Its price against peers

Against the 5 other Medical Instruments & Supplies stocks we have scored, ResMed trades at 28.0× its free cash flow, versus a median of 26.1× for that basket. On price alone, ResMed is therefore more expensive than its peers. That says nothing about its quality: at Lubin Investment, quality and price are judged separately, and a low multiple is only a bargain if the quality holds up.

Frequently asked questions

Is ResMed a quality stock?

ResMed gets a quality score of 9/10 (high quality), calculated over the 10 Lubin Investment criteria: profitability, revenue and free cash flow growth, share buybacks, margins, debt and return on capital.

How is ResMed's score calculated?

The score is the total of validated criteria (YES / PARTIAL / NO) using thresholds drawn from the financial literature (Warren Buffett, Mauboussin, Aswath Damodaran), automatically and with no human opinion.

What is ResMed's P/FCF?

The price-to-free-cash-flow (P/FCF) multiple of ResMed stock is 28.0×. At Lubin Investment, valuation is judged separately from quality.

Where to see ResMed's full analysis?

The full interactive analysis (10-criteria detail, history, P/FCF valuation, sector comparisons) is available at https://lubin-investment.com/analyse/RMD.AX?lng=en.

Other stocks in the Medical Instruments & Supplies sector

• Resmed (RMD), score 10/10, P/FCF 19.8×
• Asahi Intecc (7747.T), score 10/10, P/FCF 30.8×
• LeMaitre Vascular (LMAT), score 9/10, P/FCF 26.1×
• Fielmann Group (FIE.DE), score 9/10, P/FCF 8.6×

Go further

👉 See the full interactive analysis of RMD.AX

Other resources : All stocks in the Medical Instruments & Supplies sector.